Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2021

Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α) inhibitors are primarily reserved for moderate to severe disease that is refractory to conventional therapies or for the first-line treatment of very severe disease. Takeda’s cell adhesion molecule (CAM) inhibitor, Entyvio; Janssen’s IL-12 / IL-23 inhibitor, Stelara; and Pfizer’s JAK inhibitor, Xeljanz / Xeljanz XR are alternative options, especially for TNF-α-refractory patients. These three newer drugs are not approved for pediatric UC, but, given the limited number of therapies available for pediatric patients who fail TNF-α inhibitors, physicians may turn to them as last-line options.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric UC patients?
• How have Stelara, Entyvio, and Xeljanz / Xeljanz XR been integrated into the treatment algorithm, and what is their source of business?
• What percentage of pediatric UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of pediatric UC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Markets covered: United States

Key companies: AbbVie, Janssen, Pfizer, Salix, Takeda

Key drugs: Apriso, Entyvio, Humira, Pentasa, Remicade, Stelara, Xeljanz